April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica

Partial hold lifted on Xencor's blood cancer bispecific
FDA lifted a partial clinical hold on a Phase I trial of XmAb14045 from Xencor

Read the full 228 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE